vs

Side-by-side financial comparison of METHODE ELECTRONICS INC (MEI) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

METHODE ELECTRONICS INC is the larger business by last-quarter revenue ($246.9M vs $151.7M, roughly 1.6× Tarsus Pharmaceuticals, Inc.). METHODE ELECTRONICS INC runs the higher net margin — -4.0% vs -5.5%, a 1.5% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -15.6%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-11.6M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -2.5%).

Methode Electronics is an American multinational company headquartered in Chicago, Illinois, with engineering, manufacturing and sales operations in more than 35 locations in 14 countries. The company employs around 6,500 people worldwide.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

MEI vs TARS — Head-to-Head

Bigger by revenue
MEI
MEI
1.6× larger
MEI
$246.9M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+144.0% gap
TARS
128.4%
-15.6%
MEI
Higher net margin
MEI
MEI
1.5% more per $
MEI
-4.0%
-5.5%
TARS
More free cash flow
TARS
TARS
$24.6M more FCF
TARS
$13.0M
$-11.6M
MEI
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-2.5%
MEI

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
MEI
MEI
TARS
TARS
Revenue
$246.9M
$151.7M
Net Profit
$-9.9M
$-8.4M
Gross Margin
19.3%
Operating Margin
1.2%
-5.3%
Net Margin
-4.0%
-5.5%
Revenue YoY
-15.6%
128.4%
Net Profit YoY
-518.8%
63.8%
EPS (diluted)
$-0.28
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MEI
MEI
TARS
TARS
Q4 25
$246.9M
$151.7M
Q3 25
$240.5M
$118.7M
Q2 25
$257.1M
$102.7M
Q1 25
$239.9M
$78.3M
Q4 24
$292.6M
$66.4M
Q3 24
$258.5M
$48.1M
Q2 24
$277.3M
$40.8M
Q1 24
$259.5M
$27.6M
Net Profit
MEI
MEI
TARS
TARS
Q4 25
$-9.9M
$-8.4M
Q3 25
$-10.3M
$-12.6M
Q2 25
$-28.3M
$-20.3M
Q1 25
$-14.4M
$-25.1M
Q4 24
$-1.6M
$-23.1M
Q3 24
$-18.3M
$-23.4M
Q2 24
$-57.3M
$-33.3M
Q1 24
$-11.6M
$-35.7M
Gross Margin
MEI
MEI
TARS
TARS
Q4 25
19.3%
Q3 25
18.1%
Q2 25
7.6%
Q1 25
17.2%
Q4 24
19.8%
Q3 24
17.3%
Q2 24
12.8%
Q1 24
14.3%
Operating Margin
MEI
MEI
TARS
TARS
Q4 25
1.2%
-5.3%
Q3 25
0.5%
-12.2%
Q2 25
-9.2%
-21.6%
Q1 25
-0.9%
-33.5%
Q4 24
3.2%
-36.8%
Q3 24
-2.9%
-52.3%
Q2 24
-22.2%
-81.6%
Q1 24
-1.2%
-136.5%
Net Margin
MEI
MEI
TARS
TARS
Q4 25
-4.0%
-5.5%
Q3 25
-4.3%
-10.6%
Q2 25
-11.0%
-19.8%
Q1 25
-6.0%
-32.1%
Q4 24
-0.5%
-34.8%
Q3 24
-7.1%
-48.7%
Q2 24
-20.7%
-81.6%
Q1 24
-4.5%
-129.4%
EPS (diluted)
MEI
MEI
TARS
TARS
Q4 25
$-0.28
$-0.17
Q3 25
$-0.29
$-0.30
Q2 25
$-0.79
$-0.48
Q1 25
$-0.41
$-0.64
Q4 24
$-0.05
$-0.57
Q3 24
$-0.52
$-0.61
Q2 24
$-1.62
$-0.88
Q1 24
$-0.33
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MEI
MEI
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$118.5M
$417.3M
Total DebtLower is stronger
$332.5M
$72.4M
Stockholders' EquityBook value
$679.3M
$343.4M
Total Assets
$1.3B
$562.2M
Debt / EquityLower = less leverage
0.49×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MEI
MEI
TARS
TARS
Q4 25
$118.5M
$417.3M
Q3 25
$121.1M
$401.8M
Q2 25
$103.6M
$381.1M
Q1 25
$103.8M
$407.9M
Q4 24
$97.0M
$291.4M
Q3 24
$111.3M
$317.0M
Q2 24
$161.5M
$323.6M
Q1 24
$122.9M
$298.5M
Total Debt
MEI
MEI
TARS
TARS
Q4 25
$332.5M
$72.4M
Q3 25
$323.4M
$72.3M
Q2 25
$317.6M
$72.1M
Q1 25
$327.9M
$72.0M
Q4 24
$340.6M
$71.8M
Q3 24
$296.0M
$71.7M
Q2 24
$330.9M
$71.6M
Q1 24
$331.3M
$29.9M
Stockholders' Equity
MEI
MEI
TARS
TARS
Q4 25
$679.3M
$343.4M
Q3 25
$688.1M
$335.1M
Q2 25
$693.3M
$332.6M
Q1 25
$704.3M
$342.5M
Q4 24
$738.3M
$224.5M
Q3 24
$744.4M
$237.5M
Q2 24
$766.0M
$252.2M
Q1 24
$835.0M
$275.2M
Total Assets
MEI
MEI
TARS
TARS
Q4 25
$1.3B
$562.2M
Q3 25
$1.3B
$534.6M
Q2 25
$1.3B
$495.0M
Q1 25
$1.3B
$500.8M
Q4 24
$1.4B
$377.0M
Q3 24
$1.4B
$376.3M
Q2 24
$1.4B
$376.8M
Q1 24
$1.5B
$349.3M
Debt / Equity
MEI
MEI
TARS
TARS
Q4 25
0.49×
0.21×
Q3 25
0.47×
0.22×
Q2 25
0.46×
0.22×
Q1 25
0.47×
0.21×
Q4 24
0.46×
0.32×
Q3 24
0.40×
0.30×
Q2 24
0.43×
0.28×
Q1 24
0.40×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MEI
MEI
TARS
TARS
Operating Cash FlowLast quarter
$-7.4M
$19.3M
Free Cash FlowOCF − Capex
$-11.6M
$13.0M
FCF MarginFCF / Revenue
-4.7%
8.6%
Capex IntensityCapex / Revenue
1.7%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$52.3M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MEI
MEI
TARS
TARS
Q4 25
$-7.4M
$19.3M
Q3 25
$25.1M
$18.3M
Q2 25
$35.4M
$-29.4M
Q1 25
$28.1M
$-20.7M
Q4 24
$-48.0M
$-22.2M
Q3 24
$10.9M
$-8.7M
Q2 24
$24.9M
$-14.4M
Q1 24
$28.8M
$-37.8M
Free Cash Flow
MEI
MEI
TARS
TARS
Q4 25
$-11.6M
$13.0M
Q3 25
$18.0M
$16.3M
Q2 25
$26.3M
$-30.4M
Q1 25
$19.6M
$-21.2M
Q4 24
$-58.4M
$-22.3M
Q3 24
$-2.7M
$-8.9M
Q2 24
$15.8M
$-15.4M
Q1 24
$12.2M
$-38.0M
FCF Margin
MEI
MEI
TARS
TARS
Q4 25
-4.7%
8.6%
Q3 25
7.5%
13.8%
Q2 25
10.2%
-29.6%
Q1 25
8.2%
-27.1%
Q4 24
-20.0%
-33.5%
Q3 24
-1.0%
-18.6%
Q2 24
5.7%
-37.8%
Q1 24
4.7%
-137.5%
Capex Intensity
MEI
MEI
TARS
TARS
Q4 25
1.7%
4.2%
Q3 25
3.0%
1.6%
Q2 25
3.5%
1.0%
Q1 25
3.5%
0.8%
Q4 24
3.6%
0.1%
Q3 24
5.3%
0.6%
Q2 24
3.3%
2.5%
Q1 24
6.4%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons